Says continues to manage Humira erosion from biosimilars. Says several promising R&D programs in the pipeline. Expects “robust” revenue growth in 2025 and strong CAGR through the end of the decade. Says Botox continues to perform “very well” despite competition. Comments taken from Q3 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- Abbvie Reports Earnings: Did it Beat Estimate Forecasts?
- AbbVie (NYSE:ABBV) Exceeds Q3 Expectations; Hikes Dividend
- AbbVie raises quarterly dividend 4.7% to $1.55 from $1.48 per share
- AbbVie raises FY24 EPS guidance floor from $10.70 to $11.00, consensus $10.45
- AbbVie Reports Third-Quarter 2023 Financial Results